CVS Beats Q2 Expectations and Raises 2026 Guidance, But Shares Drop on Soft 2027 Outlook

CVS Health reports strong Q2 results with $2.58 adjusted EPS and raises 2026 guidance, but shares fall on a muted 2027 outlook and cautious cost warnings.